News and Comments

YES. GILEAD DID IT AGAIN

  Thursday, August 29, 2013

GILEAD DID IT AGAIN  More...

ARIAD: SUCCUMBING TEMPORARILY TO EXTRAORDINARY PRESSURE

  Friday, August 09, 2013

Ariad’s (ARIA) conference call and the discussions that followed confirmed our optimistic projections regarding Ariad’s leukemia drug Iclusig (ponatinib) sales. The announced exciting news, while is being met with a stock selloff, it cemented our conviction that Iclusig possesses all the features of a blockbuster and the criteria of growth, which are built through its efficacy derived from its mode of action. Iclusig has offered the oncology community a new option for hope in patients who, for a reason or another, cannot use the conventional first line treatments and those whose leukemia, or recurrent leukemia stopped responding to the currently used treatments. Although Iclusig is not officially designated a breakthrough, it is viewed as indispensable for the various kinds of leukemia it has been granted approval for, which is the main reason behind FDA granting it early approval.   More...

REGENERON'S HORSE EYELEA TRIPLES ITS SPEED

  Tuesday, August 06, 2013

Each and every time investors believed Regeneron (REGN) highest high value has been reached, like a magician, it pulled another chicken out of its long black hat and made it lay another golden egg. Regeneron’s new different egg is expected to boost its wealth, turning the current estimation upside down, i.e., from overvalued or fairly valued into undervalued.    More...


Recent Postings


Archive


Tags

Global Cell Therapeutics (GBT) PTC Therapeutics (PTCT) Agenus (AGEN Onyx (ONXX) Dendreon (DNDN) Bellicum (BLCM) NEKTAR (NKTR)) ADVENTRIX (ANX) Sanofi (SNA) AERIE PHARMACEUTICALS Trastuzumab-DM1 GlaxoSmithKline (GSK) Sequenom (SQNM) Regeneron (REGN) GUARDIAN HEALTH AGOS (ARGS) Vitae Pharmaceuticals (VTAE) Bristol-Myers Squibb (BMY) Endometrial Cancer Ridaforolimus JUNO (JUNO) Cytokinetics (CYTK) Gilead (GILD) Advaxis (ADXS) CompuGen (CGEN) Jazz Pharmaceuticals (JAZZ) Micromet (MITI) Elan (ELN) Theravance Bio Pharma (TBPH) INNOVIVA (INVA) Galena (GALE) Array Pharmaceuticals (ARRY) ABBVIE (ABBV) Genentech SUNESIS PHARMACEUTICALS (SNSS) Prolor Biotech (PBTH) MODERNA Herceptin Theravance (THRX) Alder Biopharmaceuticals (ALDR) Sangamo (SGMO) Anadys (ANDS) Sanofi-Aventis (SAN) HALOZYME (HALO) CEMPRA (CEMP) IDERA (IDRA) CRISPR Therapeutics (CRSP) KERYX (KERX) Tysabri Valeant Pharmaceuticals International (VRX) Adaptimmune (ADAP) Editas (EDIT) Exelixis (EXEL) SERES THERAPEUTICS (MCRB) SYNTA (SNTA) Roche (ROCHE) ImmunoGen (IMGN) ACADIA (ACAD) VANDA (VNDA) RenenxBio (RGNX) ARCA (ABIO) Idenix (IDIX) Ziofpharm (ZIOP) galapagos (GLPG) Agenus (AGEN) Intermune (ITMN) Amgen (AMGN) Dynavax (DVAX) Spike Therapeutics (ONCE) Intrexon (XON) Alnylam (ALNY) Multiple Myeloma Human Genome Sciences (HGSI) OSI (OSIP) Benlysta (belimumab) Intercept (ICPT) Revlimid (lenolidamide) Pluristem (PSTI) Mirati Therapeutics (MRTX) REGULUS (RGLS) AstraZeneca (AZN) Human Longevity (HLI) Merck (MRK) Illumina (ILMN) ARGOS (ARGS) NANTKWEST (NK) Biocryst (BCRX) Inovio (INO) Prosensa (RNA) Sanofi (SNY) BIOMARIN (BMRN) Seattle Genetics (SGEN) Velcade (bortezomib) Anacor (ANAC) Rapamune Incyte (INCY) NOVOCURE (NVCR) TOKAI (TKAOI) ZALTRAP™ Xoma (XOMA) Auspex (ASPX) Roche (RHHBY) Biogen Idec (BIIB) Sarepta (SRPT) Abbott Laboratories (ABT) Vertex (VRTX) C4 Therapeutics Aimmune Therapeutics (AIMT) Zerenex Ariad (ARIA) KITE (KITE) ISIS (ISIS) Telaprevir Ocular Therapeutix (OCUL) Ionis (IONS)